169 related articles for article (PubMed ID: 38116495)
1. A Case Report of Anti-TIF1-
Hounoki H; Onose T; Yamazaki M; Asano R; Yamaguchi S; Shinoda K; Tobe K; Noguchi A; Hirabayashi K
Case Rep Rheumatol; 2023; 2023():8837463. PubMed ID: 38116495
[TBL] [Abstract][Full Text] [Related]
2. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
4. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
6. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
8. Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture.
Saraya T; Tamura M; Kasuga K; Fujiwara M; Takizawa H
Respirol Case Rep; 2019 Apr; 7(3):e00403. PubMed ID: 30766682
[TBL] [Abstract][Full Text] [Related]
9. Two cases of dermatomyositis associated with neuroendocrine tumors.
Shani U; Lavine N; Houri-Levi E; Watad A; Amital H
Int Cancer Conf J; 2024 Jan; 13(1):17-21. PubMed ID: 38187177
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
12. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
14. [Juvenile-onset anti-nuclear matrix protein 2 (NXP-2) antibody-positive dermatomyositis with joint contractures before manifestation of myositis: a case report].
Miura E; Taneda T; Umeda Y; Umeda M; Oyake M; Matsushita T; Nishino I; Fujita N
Rinsho Shinkeigaku; 2024 May; ():. PubMed ID: 38797685
[TBL] [Abstract][Full Text] [Related]
15. SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report.
Arnon J; Elia A; Nevo Y; Lossos A; Nechushtan H
JTO Clin Res Rep; 2021 Sep; 2(9):100217. PubMed ID: 34590056
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence.
Ferronato M; Lalanne C; Quarneti C; Cevolani M; Ricci C; Granito A; Muratori L; Lenzi M
J Clin Transl Hepatol; 2023 Feb; 11(1):253-259. PubMed ID: 36406323
[TBL] [Abstract][Full Text] [Related]
19. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
Yamaguchi Y; Aso M; Nagasawa H; Wada M
Intern Med; 2021 Sep; 60(18):3025-3029. PubMed ID: 33776010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
